uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
What treatments should be skipped or intensified in localized rectal cancer?
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology.ORCID iD: 0000-0002-5440-791x
2018 (English)In: Future Oncology, ISSN 1479-6694, E-ISSN 1744-8301, Vol. 14, no 4, p. 313-318Article in journal, Editorial material (Other academic) Published
Place, publisher, year, edition, pages
2018. Vol. 14, no 4, p. 313-318
Keywords [en]
adjuvant chemotherapy, chemoradiotherapy, organ perseveration, radiotherapy, rectal cancer, risk grouping
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-355834DOI: 10.2217/fon-2017-0492ISI: 000427262600002PubMedID: 29318918OAI: oai:DiVA.org:uu-355834DiVA, id: diva2:1231502
Available from: 2018-07-06 Created: 2018-07-06 Last updated: 2018-07-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Glimelius, Bengt

Search in DiVA

By author/editor
Glimelius, Bengt
By organisation
Experimental and Clinical Oncology
In the same journal
Future Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 21 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf